Published: Guidance, quality standards and advice

Showing 31 to 40 of 42

Sort by

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib	TA586	26 June 2019	26 June 2019
Lenalidomide plus dexamethasone for previously untreated multiple myeloma	TA587	26 June 2019	26 June 2019
Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal)	TA549	5 December 2018	5 December 2018
Myeloma: diagnosis and management	NG35	10 February 2016	25 October 2018
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)	TA454	5 July 2017	5 July 2017
Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal)	TA453	5 July 2017	5 July 2017
Elotuzumab for previously treated multiple myeloma (terminated appraisal)	TA434	22 March 2017	22 March 2017
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib	TA427	11 January 2017	11 January 2017
Panobinostat for treating multiple myeloma after at least 2 previous treatments	TA380	27 January 2016	27 January 2016
Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation	TA311	23 April 2014	23 April 2014